ReviewIBRO neuroscience reports2026
Cortical transcriptomic dysregulation in Autism spectrum disorder: A conceptual synthesis.
Review in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition in which human post-mortem cortical transcriptomic studies have identified recurrent but context-sensitive molecular abnormalities. This narrative review synthesises RNA sequencing (RNA-seq) evidence from ASD cortex and organises recurrent findings into three interacting cortical domains: synaptic/neuronal programmes, immune-glial programmes, and RNA-regulatory processes. Across bulk cortical datasets, the most reproducible signals include relative downregulation of neuronal and synaptic expression programmes together with upregulation of glial-associated and neuroimmune signatures, whereas transcript-level analyses further implicate alternative splicing, microexon dysregulation, differential transcript usage, and isoform-level perturbation. Single-nucleus and related cell-resolved approaches localise these abnormalities to defined neuronal and glial populations, while long-read strategies strengthen inference on transcript structure and isoform complexity. Within this framework, mitochondrial-related findings are best interpreted as a linked bioenergetic component rather than an equally established standalone transcriptomic domain. The review also summarise the principal interpretive constraints of cortical ASD transcriptomics, including region specificity, developmental stage, cohort heterogeneity, cell-type composition, post-mortem tissue quality, and cross-platform comparability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.